Lecturer on Psychiatry, McLean Hospital

Psychiatry

Frances Frankenburg works in the field of Psychiatry. Frances R. Frankenburg is a published doctor as well. She has 101 publications published. The latest was: Axis I comorbidity of borderline personality disorder.

Publications

---

• Development of the self-report version of the Zanarini Rating Scale for Borderline Personality Disorder.
• Treatment rates for patients with borderline personality disorder and other personality disorders: a 16-year study.
• Pain in patients with borderline personality disorder.
• The 16-year course of shame and its risk factors in patients with borderline personality disorder.
• Prediction of time-to-attainment of recovery for borderline patients followed prospectively for 16 years.
• Prevalence and risk factors for irritable bowel syndrome in recovered and non-recovered borderline patients over 10 years of prospective follow-up.
• The use of prescription opioid medication by patients with borderline personality disorder and axis II comparison subjects: a 10-year follow-up study.
• Relationship between maladaptive cognitions about sleep and recovery in patients with borderline personality disorder.
• The relationship of chronic medical illnesses, poor health-related lifestyle choices, and health care utilization to recovery status in borderline patients over a deca...
• Predictors of suicide threats in patients with borderline personality disorder over 16 years of prospective follow-up.
• Cognitive experiences reported by patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study.
• Relationship between sleep disturbance and recovery in patients with borderline personality disorder.
• Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year...
• Relationship Between Cumulative BMI and Symptomatic, Psychosocial, and Medical Outcomes in Patients with Borderline Personality Disorder.
• Time to attainment of recovery from borderline personality disorder and stability of recovery: A 10-year prospective follow-up study.
• Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders.
• A longitudinal study of the 10-year course of interpersonal features in borderline personality disorder.
• The course of eating disorders in patients with borderline personality disorder: a 10-year follow-up study.
• Sedative-hypnotic use in patients with borderline personality disorder and axis II comparison subjects.
• The 10-year course of social security disability income reported by patients with borderline personality disorder and axis II comparison subjects.
• Family history study of the familial coaggregation of borderline personality disorder with axis I and nonborderline dramatic cluster axis II disorders.
• Folate supplementation: is it safe and effective?
• Defense mechanisms associated with borderline personality disorder.
• Case 20-2008: Abdominal pain and weakness after gastric bypass surgery.
• Alcohol use, thiamine deficiency, and cognitive impairment.
• A preliminary, randomized trial of psychoeducation for women with borderline personality disorder.
• Neurosyphilis, malaria, and the discovery of antipsychotic agents.
• The essential nature of borderline psychopathology.
• The role of one-carbon metabolism in schizophrenia and depression.
• The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study.
• Personality disorders and medical comorbidity.
• Prediction of the 10-year course of borderline personality disorder.
• Reported childhood onset of self-mutilation among borderline patients.
• Obesity and obesity-related illnesses in borderline patients.
• Smoking cessation.
• The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up.
• Adult experiences of abuse reported by borderline patients and Axis II comparison subjects over six years of prospective follow-up.
• Psychosocial functioning of borderline patients and axis II comparison subjects followed prospectively for six years.
• The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization.
• Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission.
• Borderline psychopathology in the first-degree relatives of borderline and axis II comparison probands.
• Pharmacological treatment of delirium in the intensive care unit.
• A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
• Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years.
• A screening measure for BPD: the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD).
• Sexual relationship difficulties among borderline patients and axis II comparison subjects.
• Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology.
• The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.
• omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
• Severity of reported childhood sexual abuse and its relationship to severity of borderline psychopathology and psychosocial impairment among borderline inpatients.
• Inter-rater and test-retest reliability of the Revised Diagnostic Interview for Borderlines.
• Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
• Combined Clozapine and Electroconvulsive Therapy.
• Is any measurable blood lead level harmful?
• Predictors of self-mutilation in patients with borderline personality disorder: A 10-year follow-up study.
• Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.
• Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study.
• Treatment histories of borderline inpatients.
• Biparental failure in the childhood experiences of borderline patients.
• The dissociative experiences of borderline patients.
• Risk factors associated with the dissociative experiences of borderline patients.
• Choices in antipsychotic therapy in schizophrenia.
• The pain of being borderline: dysphoric states specific to borderline personality disorder.
• Is clozapine worth its cost?
• Violence in the lives of adult borderline patients.
• Axis I comorbidity of borderline personality disorder.
• Axis II comorbidity of borderline personality disorder.
• Clozapine and body mass change.
• Uses of clozapine in nonschizophrenic patients.
• Reported pathological childhood experiences associated with the development of borderline personality disorder.
• Pathways to the development of borderline personality disorder.
• Cardiorespiratory problems with clozapine.
• The effect of clozapine on saliva flow rate: a pilot study.
• Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
• Clozapine-caused eosinophilic colitis.
• Bladder dysfunction associated with clozapine therapy.
• Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography.
• Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.
• Clozapine in the elderly.
• Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients.
• Clozapine treatment of borderline patients: a preliminary study.
• Clozapine and seizures: a review.
• Tinnitus, psychosis, and suicide.
• Unsuccessful reexposure to clozapine.
• History of the development of antipsychotic medication.
• Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome.
• Fever associated with clozapine administration.
• Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites.
• Ontario Mental Health Act.
• The history of the confinement of the mentally ill in Ontario.
• Hoarding in anorexia nervosa.
• Dressing disorder.
• Preparation for the certification examination.
• Open trial of S-adenosylmethionine for treatment of depression.
• Issues in the therapy of hearing children with deaf parents.
• The diagnostic Interview for Personality Disorders: interrater and test-retest reliability.
• Fever caused by lithium in a patient with neuroleptic malignant syndrome.
• Psychosis and prenatal exposure to diethylstilbestrol.
• Is bulimia associated with borderline personality disorder? A controlled study.
• A controlled study of lifetime prevalence of affective and other psychiatric disorders in bulimic outpatients.

Schools

---

• University of Toronto Faculty of Medicine

• Toronto General Hospital

• McLaughlin Fdn McLean Hospital

• University Toronto

• McLean Hospital

Doctors Specialties

---

• Psychiatry

Accepted Insurances

---

Education

---

• University of Toronto Faculty of Medicine

Hospital

---

• McLean Hospital

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Dennis M. O'Neil, MD
	Dr. Rosanne B. Schipani, MD
	Dr. Lawrence J. Bobrin, MD This Doctor is OpenDoctor Recommended.
	Dr. Katherine Ackerman, MD This Doctor is OpenDoctor Recommended.
	Dr. Stuart C. Rosenthal, MD
	Dr. William L. Burch, MD
	Dr. Stanley F. Wallace, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog